Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 16:9:876546.
doi: 10.3389/fcvm.2022.876546. eCollection 2022.

Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor

Nikolas Nozica  1 , George C M Siontis  1 , Elena Georgieva Elchinova  1 , Eleni Goulouti  1 , Masahiko Asami  2 , Joanna Bartkowiak  1 , Samuel Baldinger  1 , Helge Servatius  1 , Jens Seiler  1 , Hildegard Tanner  1 , Fabian Noti  1 , Andreas Haeberlin  1 , Mattia Branca  3 , Jonas Lanz  1 , Stefan Stortecky  1 , Thomas Pilgrim  1 , Stephan Windecker  1 , Tobias Reichlin  1 , Fabien Praz  1 , Laurent Roten  1
Affiliations

Assessment of New Onset Arrhythmias After Transcatheter Aortic Valve Implantation Using an Implantable Cardiac Monitor

Nikolas Nozica et al. Front Cardiovasc Med. .

Abstract

Background: Transcatheter aortic valve implantation (TAVI) is associated with new onset brady- and tachyarrhythmias which may impact clinical outcome.

Aims: To investigate the true incidence of new onset arrhythmias within 12 months after TAVI using an implantable cardiac monitor (ICM).

Methods: One hundred patients undergoing TAVI received an ICM within 3 months before or up to 5 days after TAVI. Patients were followed-up for 12 months after discharge from TAVI for the occurrence of atrial fibrillation (AF), bradycardia (≤30 bpm), advanced atrioventricular (AV) block, sustained ventricular and supraventricular tachycardia.

Results: A previously undiagnosed arrhythmia was observed in 31 patients (31%) and comprised AF in 19 patients (19%), advanced AV block in 3 patients (3%), and sustained supraventricular and ventricular tachycardia in 10 (10%) and 2 patients (2%), respectively. Three patients had a clinical diagnosis of sick-sinus-syndrome. A permanent pacemaker (PPM) was implanted in six patients (6%). The prevalence of pre-existing AF was 28%, and 47% of the patients had AF at the end of the study period. AF burden was significantly higher in patients with pre-existing [26.7% (IQR 0.3%; 100%)] compared to patients with new-onset AF [0.0% (IQR 0.0%; 0.06%); p = 0.001]. Three patients died after TAVI without evidence of an arrhythmic cause according to the available ICM recordings.

Conclusions: Rhythm monitoring for 12 months after TAVI revealed new arrhythmias, mainly AF, in almost one third of patients. Atrial fibrillation burden was higher in patients with prevalent compared to incident AF. Selected patients may benefit from short-term remote monitoring.

Trial registration: https://clinicaltrials.gov/: NCT02559011.

Keywords: AV block; TAVI; atrial fibrillation; bundle branch block (BBB); implantable cardiac monitor (ICM); pacemaker (PM); ventricular tachycardia (VT).

PubMed Disclaimer

Conflict of interest statement

The spouse of JS is an employee of Boston Scientific. HT reports educational grants from Biosense Webster and travel grants from Abbott. FN reports travel fees from Medtronic, Abbott, Boston Scientific and Philips Spectranetics, speaker fees from Medtronic and Abbott, educational grants from Medtronic, Abbott, Boston Scientific, Philips Spectranetics and Actinno and institutional grants from Biotronik. AH received travel/educational grants from Medtronic and Philips/Spectranetics. He is consultant/advisor for DiNAQOR and Biotronik and Co-founder/head of Act-Inno. SS reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott, as well as personal fees from Boston Scientific, Teleflex and BTG. TP reports research grants to the institution from Biotronik, Boston Scientific and Edwards Lifesciences; speaker fees from Biotronik and Boston Scientific; Clinical event committee for study sponsored by HighLifeSAS; travel reimbursement from Medira; proctoring for Medtronic. SW reports research and educational grants to the institution from Abbott, Amgen, Astra Zeneca, BMS, Bayer, Biotronik, Boston Scientific, Cardinal Health, CardioValve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Johnson & Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi-Aventis, Sinomed, Terumo, V-Wave. He serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, Terumo, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. TR reported research grants from the Goldschmidt-Jacobson Foundation, the Swiss National Science Foundation, the Swiss Heart Foundation and the sitem-insel Support Funds, all for work outside the submitted study; advisory board membership, speaker and travel support from Abbott/SJM, Astra Zeneca, Brahms, Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Medtronic, Pfizer-BMS and Roche, all for work outside the submitted study and without impact on his personal remuneration; as well as support for his institution's fellowship program from Abbott/SJM, Biosense-Webster, Biotronik, Boston-Scientific and Medtronic for work outside the submitted study and without impact on his personal remuneration. FP reports travel expenses from Abbott Vascular, Edwards Lifesciences, and Polares Medical. LR received speaker honoraria from Abbott/SJM and consulting honoraria from Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
(A) Kaplan-Meier survival curve free of any new arrhythmia recorded by the ICM after TAVI. (B) Kaplan-Meier survival curve free of atrial fibrillation and new-onset atrial fibrillation after implantation of an implantable cardiac monitor.
See this image and copyright information in PMC

References

    1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. . Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. (2010) 363:1597–607. 10.1056/NEJMoa1008232 - DOI - PubMed
    1. Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al. . 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J. Am. Coll. Cardiol. (2016) 67:2565–74. 10.1016/j.jacc.2016.03.506 - DOI - PubMed
    1. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. . Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. (2011) 364:2187–98. 10.1056/NEJMoa1103510 - DOI - PubMed
    1. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. . 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. (2015) 385:2477–84. 10.1016/S0140-6736(15)60308-7 - DOI - PubMed
    1. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. . Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. (2017) 376:1321–31. 10.1056/NEJMoa1700456 - DOI - PubMed

Associated data